Market Overview

Morgan Stanley Asks: How Fast Will Priceline Grow Next Quarter?


Priceline Group Inc (NASDAQ: PCLN) reported better-than-expected 1Q16 non-GAAP EPS and accelerated bookings. Morgan Stanley’s Brian Nowak maintained an Equal-Weight rating for the company, with a price target of $1,330.

Strong 1Q Beat But A Noisy 2Q Guide

Apart from recording robust 1Q16 bookings and higher-than-expected non-GAAP EPS, Priceline reported solid ROIs for performance marketing, which were better than the guidance. This indicates that the company’s advertising spend continues to yield results, analyst Brian Nowak commented.

Although the top-end of Priceline’s 2Q total ex-FX bookings growth, of 11-18 percent, was lower than the estimates, the company continues to have relatively high visibility with an average booking window of 30-45 days. Priceline also tends to be conservative, the analyst added.

Priceline’s profitability guidance fell short of expectations. The company guided to 2Q adjusted EBITDA of $740-$795 million. This lower 2Q profitability is expected to be on account of increased branded ad spending on TV ad digital, the Easter shift, continued hiring in the core OTA business and performance advertising spend.

The non-GAAP EPS estimates for FY16 and FY17 have been reduced by 3 percent and 5 percent, respectively. The share-repurchase assumptions for 2016 have been reduced from $2.25 billion to $1.2 billion.

Latest Ratings for PCLN

Feb 2018MaintainsHoldHold
Jan 2018MaintainsMarket PerformMarket Perform
Dec 2017DowngradesBuyNeutral

View More Analyst Ratings for PCLN
View the Latest Analyst Ratings

Posted-In: Brian Nowak Morgan StanleyAnalyst Color Reiteration Analyst Ratings


Related Articles (PCLN)

View Comments and Join the Discussion!

Latest Ratings

WUBABOCOM InternationalDowngrades
DLTROTR GlobalUpgrades
ARCCCompass PointDowngrades
GTYHCitiInitiates Coverage On7.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Mid-Morning Market Update: Markets Edge Higher; Merck Profit Beats Views

Are We Seeing A Sector Rotation Away From Financials And Into Healthcare?